Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer.

Trial Profile

Single Arm Study of the Combination of Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Docetaxel; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms AINO
  • Most Recent Events

    • 01 Dec 2016 Results published in the Anticancer Research
    • 27 Apr 2016 Status changed from recruiting to completed.
    • 20 Mar 2012 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top